Developmental Neuroscience

Original Paper

Differentiated Dopaminergic MN9D Cells Only Partially Recapitulate the Electrophysiological Properties of Midbrain Dopaminergic Neurons

Rick C.E.a · Ebert A.b · Virag T.b · Bohn M.C.b · Surmeier D.J.a

Author affiliations

aPhysiology Department, Feinberg School of Medicine, Northwestern University, and bDepartment of Pediatrics, Children’s Memorial Research Center, Neurobiology Program, Chicago, Ill., USA

Related Articles for ""

Dev Neurosci 2006;28:528–537

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 9.00 *
EUR 8.00 *
USD 9.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: November 28, 2005
Accepted: January 20, 2006
Published online: October 06, 2006
Issue release date: October 2006

Number of Print Pages: 10
Number of Figures: 6
Number of Tables: 1

ISSN: 0378-5866 (Print)
eISSN: 1421-9859 (Online)

For additional information: https://www.karger.com/DNE

Abstract

The cell line MN9D, a fusion of embryonic ventral mesencephalic and neuroblastoma cells, is extensively used as a model of dopamine (DA) neurons because it expresses tyrosine hydroxylase and synthesizes and releases DA. These cells are also used to test mechanisms and potential therapeutics relevant to the loss of DA neurons in Parkinson’s disease. To date, little work has been done to determine whether MN9D cells electrophysiologically resemble mature DA neurons. We examined sodium, calcium and potassium currents in undifferentiated and differentiated MN9D cells, and compared these to those found in acutely dissociated mouse substantia nigra pars compacta DA neurons. It was observed that undifferentiated MN9D cells bore no resemblance to DA neurons. Upon differentiation with butyric acid with or without a prior treatment with glial cell line-derived neurotrophic factor, differentiated MN9D cells produce an electrophysiological profile that more closely resembles substantia nigra pars compacta DA neurons even though the A-type potassium current remains noticeably absent. These observations demonstrate that undifferentiated MN9D cells are not reasonable models of DA neurons. Although differentiated MN9D cells are closer to the mature DA neuronal phenotype, they do not fully mimic DA neurons and are likely to be of questionable value as a model because of their substantive differences, including the lack of the characteristic A-type potassium current. The future use of one or a combination of growth or other factors to differentiate MN9D cells may yield a more useful model system for Parkinson’s disease studies in vitro.

© 2006 S. Karger AG, Basel




Related Articles:


References

  1. Bargas J, Howe A, Eberwine J, Cao Y, Surmeier DJ (1994): Cellular and molecular characterization of Ca2+ currents in acutely isolated, adult rat neostriatal neurons. J Neurosci 14:6667–6686.
  2. Castro DS, Hermanson E, Joseph B, Wallen A, Aarnisalo P, Heller A, Perlmann T (2001): Induction of cell cycle arrest and morphological differentiation by Nurr1 and retinoids in dopamine MN9D cells. J Biol Chem 276:43277–43284.
  3. Choi WS, Eom DS, Han BS, Kim WK, Han BH, Choi EJ, Oh TH, Markelonis GJ, Cho JW, Oh YJ (2004): Phosphorylation of p38 MAPK induced by oxidative stress is linked to activation of both caspase-8- and -9-mediated apoptotic pathways in dopaminergic neurons. J Biol Chem 279:20451–20460.
  4. Choi WS, Lee EH, Chung CW, Jung YK, Jin BK, Kim SU, Oh TH, Saido TC, Oh YJ (2001): Cleavage of Bax is mediated by caspase-dependent or -independent calpain activation in dopaminergic neuronal cells: protective role of Bcl-2. J Neurochem 77:1531–1541.
  5. Choi HK, Won LA, Kontur PJ, Hammond DN, Fox AP, Wainer BH, Hoffmann PC, Heller A (1991): Immortalization of embryonic mesencephalic dopaminergic neurons by somatic cell fusion. Brain Res 552:67–76.
  6. Choi WS, Yoon SY, Oh TH, Choi EJ, O’Malley KL, Oh YJ (1999): Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J Neurosci Res 57:86–94.
  7. Connor JA, Stevens CF (1971): Prediction of repetitive firing behaviour from voltage clamp data on an isolated neurone soma. J Physiol 213:31–53.
  8. Cuisset L, Tichonicky L, Delpech M (1998): A protein phosphatase is involved in the inhibition of histone deacetylation by sodium butyrate. Biochem Biophys Res Commun 246:760–764.
  9. Ebert AD, Chen F, He X, Cryns VL, Bohn MC (2005): A tetracycline-regulated adenovirus encoding dominant-negative caspase-9 is regulated in rat brain and protects against neurotoxin-induced cell death in vitro, but not in vivo. Exp Neurol 191(Suppl 1):S80–S94.
    External Resources
  10. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ (1981): Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391:85–100.
  11. Hansford LM, Marshall GM (2005): Glial cell line-derived neurotrophic factor (GDNF) family ligands reduce the sensitivity of neuroblastoma cells to pharmacologically induced cell death, growth arrest and differentiation. Neurosci Lett 389:77–82.
  12. Heller A, Price S, Won L (1996): Glial-derived neurotrophic factor (GDNF) induced morphological differentiation of an immortalized monoclonal hybrid dopaminergic cell line of mesencephalic neuronal origin. Brain Res 725:132–136.
  13. Henneberry RC, Fishman PH (1976): Morphological and biochemical differentiation in HeLa cells. Effects of cycloheximide on butyrate-induced process formation and ganglioside metabolism. Exp Cell Res 103:55–62.
  14. Hermanson E, Joseph B, Castro D, Lindqvist E, Aarnisalo P, Wallen A, Benoit G, Hengerer B, Olson L, Perlmann T (2003): Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells. Exp Cell Res 288:324–334.
  15. Hirata Y, Kiuchi K (2003): Mitogenic effect of glial cell line-derived neurotrophic factor is dependent on the activation of p70S6 kinase, but independent of the activation of ERK and up-regulation of Ret in SH-SY5Y cells. Brain Res 983:1–12.
  16. Holtz WA, O’Malley KL (2003): Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J Biol Chem 278:19367–19377.
  17. Liang Q, Liou AK, Ding Y, Cao G, Xiao X, Perez RG, Chen J (2004): 6-Hydroxydopamine induces dopaminergic cell degeneration via a caspase-9-mediated apoptotic pathway that is attenuated by caspase-9dn expression. J Neurosci Res 77:747–761.
  18. Liss B, Franz O, Sewing S, Bruns R, Neuhoff H, Roeper J (2001): Tuning pacemaker frequency of individual dopaminergic neurons by Kv4.3L and KChip3.1 transcription. EMBO J 20:5715–5724.
  19. Nedergaard S, Flatman JA, Engberg I (1993): Nifedipine and omega-conotoxin-sensitive Ca2+ conductances in guinea-pig substantia nigra pars compacta neurones. J Physiol 466:727–747.
  20. Oh YJ, Swarzenski BC, O’Malley KL (1996): Overexpression of Bcl-2 in a murine dopaminergic neuronal cell line leads to neurite outgrowth. Neurosci Lett 202:161–164.
  21. Riggs MG, Whittaker RG, Neumann JR, Ingram VM (1977): n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268:462–464.
  22. Segal M, Rogawski MA, Barker JL (1984): A transient potassium conductance regulates the excitability of cultured hippocampal and spinal neurons. J Neurosci 4:604–609.
  23. Surmeier DJ, Bargas J, Hemmings HCJ, Nairn AC, Greengard P (1995): Modulation of calcium currents by a D1 dopaminergic protein kinase/phosphatase cascade in rat neostriatal neurons. Neuron 14:385–397.
  24. Surmeier DJ, Mercer JN, Chan CS (2005): Autonomous pacemakers in the basal ganglia: who needs excitatory synapses anyway? Curr Opin Neurobiol 15:312–318.
  25. Tukey JW (1977): Some thoughts on clinical trials, especially problems of multiplicity. Science 198:679–684.
  26. Ugarte SD, Lin E, Klann E, Zigmond MJ, Perez RG (2003): Effects of GDNF on 6-OHDA-induced death in a dopaminergic cell line: modulation by inhibitors of PI3 kinase and MEK. J Neurosci Res 73:105–112.
  27. Wilson CJ, Callaway JC (2000): Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J Neurophysiol 83:3084–3100.
  28. Wilson DL, Morimoto K, Tsuda Y, Brown AM (1983): Interaction between calcium ions and surface charge as it relates to calcium currents. J Membr Biol 72:117–130.
  29. Worby C, Vega Q, Zhao Y, Chao H, Seasholtz A, Dixon J (1996): Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen-activated protein kinase. J Biol Chem 271:23619–23622.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: November 28, 2005
Accepted: January 20, 2006
Published online: October 06, 2006
Issue release date: October 2006

Number of Print Pages: 10
Number of Figures: 6
Number of Tables: 1

ISSN: 0378-5866 (Print)
eISSN: 1421-9859 (Online)

For additional information: https://www.karger.com/DNE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP